Crispr Therapeutics AG (CRSP) Insider Sells $1,849,980.00 in Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 66,000 shares of Crispr Therapeutics stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total value of $1,849,980.00. Following the transaction, the insider now directly owns 25,204 shares in the company, valued at $706,468.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.64, for a total value of $822,320.00.
  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.75, for a total value of $15,225.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $22.72, for a total value of $704,320.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.90, for a total value of $283,500.00.

Crispr Therapeutics AG (NASDAQ:CRSP) opened at $29.73 on Friday. Crispr Therapeutics AG has a twelve month low of $11.63 and a twelve month high of $30.96.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. During the same period in the prior year, the firm posted ($2.77) earnings per share. The firm’s revenue for the quarter was up 54.2% on a year-over-year basis. analysts anticipate that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Allianz Asset Management GmbH bought a new stake in Crispr Therapeutics in the 3rd quarter worth approximately $2,384,000. Granahan Investment Management Inc. MA increased its stake in Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after acquiring an additional 89,839 shares during the last quarter. Adams Street Partners LLC bought a new stake in Crispr Therapeutics in the 3rd quarter worth approximately $1,019,000. Ipswich Investment Management Co. Inc. bought a new stake in Crispr Therapeutics in the 4th quarter worth approximately $1,133,000. Finally, Hershey Trust Co. bought a new stake in Crispr Therapeutics in the 3rd quarter worth approximately $768,000. 21.91% of the stock is currently owned by institutional investors.

A number of research analysts recently commented on the company. Piper Jaffray Companies reissued a “buy” rating and issued a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday, January 10th. Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, December 21st. SunTrust Banks reissued a “hold” rating and issued a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Finally, BidaskClub raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $22.81.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.truebluetribune.com/2018/01/21/crispr-therapeutics-ag-crsp-insider-sells-1849980-00-in-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply